CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
1 research outputs found
Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials
Author
A Becker-Merok
A Sutherland
+60Â more
Arunan Kaliyaperumal
AS Korganow
B Huard
B Schiemann
BH Rovin
Blaire Cooke
C Bossen
C Collins
C Jacob
C Pena-Rossi
C Reinsch
D Wallace
DA Isenberg
Daniel J. Wallace
Debra J. Zack
Donna Holloway
E Tan
Ellen M. Ginzler
Erik Rasmussen
F Mackay
G Cheema
H Hsu
J Groom
J Gross
J Gross
J Thompson
J Zhang
Jill Buyon
Joan T. Merrill
John Ferbas
JT Merrill
Kameswara Rao Kuchimanchi
KP Baker
L Ng
M Batten
M Dall’Era
M Hochberg
M Petri
M Ramanujam
Michael H. Weisman
N Kayagaki
P Tak
R Do
R Furie
R Looney
R. John Looney
S Belouski
S Hong
S Ju
S Khare
S Navarra
S Sato
Shelley S. Belouski
Tsui Chern Cheah
W Stohl
W Stohl
W Stohl
Wayne Tsuji
William Stohl
X Zhou
Publication venue
'Springer Science and Business Media LLC'
Publication date
Field of study
Full text link
Crossref